Literature DB >> 22760656

Liver toxicity of antiretroviral drugs.

Michelle Jones1, Marina Núñez.   

Abstract

Drug-induced liver injury (DILI) associated with antiretroviral treatment has represented an important side effect since the beginning of the HAART era. The lack of standard definition and specific markers makes assessment of DILI very challenging. Several clinical syndromes of DILI have been described over the years; the pathogenic mechanisms are not fully understood. Better knowledge of DILI, identification of high-risk patients using pharmacogenetics, and the availability of antiretroviral agents with improved safety profile have all contributed to decrease the incidence of DILI and to ameliorate its effects. Nevertheless, with an aging human immunodeficiency virus- (HIV-) infected population and increased survival, DILI will probably continue to represent a relevant entity in e HIV therapeutic management. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22760656     DOI: 10.1055/s-0032-1316472

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  23 in total

1.  Genome-Wide Association and Replication Study of Hepatotoxicity Induced by Antiretrovirals Alone or with Concomitant Anti-Tuberculosis Drugs.

Authors:  Zelalem Petros; Ming Ta Michael Lee; Atsushi Takahashi; Yanfei Zhang; Getnet Yimer; Abiy Habtewold; Ina Schuppe-Koistinen; Taisei Mushiroda; Eyasu Makonnen; Michiaki Kubo; Eleni Aklillu
Journal:  OMICS       Date:  2017-04

2.  Mitochondrial (dys)function - a factor underlying the variability of efavirenz-induced hepatotoxicity?

Authors:  M Polo; F Alegre; H A Funes; A Blas-Garcia; V M Victor; J V Esplugues; N Apostolova
Journal:  Br J Pharmacol       Date:  2015-01-08       Impact factor: 8.739

3.  Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation in CYP2B6*6*6 Allele Carriers.

Authors:  Ahmed M Abdelhady; Tyler Shugg; Nancy Thong; Jessica Bo Li Lu; Yvonne Kreutz; Heather A Jaynes; Jason D Robarge; James E Tisdale; Zeruesenay Desta; Brian R Overholser
Journal:  J Cardiovasc Electrophysiol       Date:  2016-07-25

Review 4.  Endoplasmic reticulum stress in drug- and environmental toxicant-induced liver toxicity.

Authors:  Si Chen; William B Melchior; Lei Guo
Journal:  J Environ Sci Health C Environ Carcinog Ecotoxicol Rev       Date:  2014       Impact factor: 3.781

Review 5.  Pros and cons of liver transplantation in human immunodeficiency virus infected recipients.

Authors:  Umberto Baccarani; Elda Righi; Gian Luigi Adani; Dario Lorenzin; Alberto Pasqualucci; Matteo Bassetti; Andrea Risaliti
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

6.  Effect of Human Immunodeficiency Virus on Trace Elements in the Brain.

Authors:  Karen Cilliers; Christo J F Muller
Journal:  Biol Trace Elem Res       Date:  2020-04-01       Impact factor: 3.738

7.  Potential health impacts of heavy metals on HIV-infected population in USA.

Authors:  Xiaohui Xu; Hui Hu; Amy B Dailey; Greg Kearney; Evelyn O Talbott; Robert L Cook
Journal:  PLoS One       Date:  2013-09-02       Impact factor: 3.240

8.  Nano-NRTIs demonstrate low neurotoxicity and high antiviral activity against HIV infection in the brain.

Authors:  Trevor Gerson; Edward Makarov; Thulani H Senanayake; Santhi Gorantla; Larisa Y Poluektova; Serguei V Vinogradov
Journal:  Nanomedicine       Date:  2013-07-09       Impact factor: 5.307

Review 9.  Nanoparticle delivery system, highly active antiretroviral therapy, and testicular morphology: The role of stereology.

Authors:  Edwin Coleridge S Naidu; Samuel Oluwaseun Olojede; Sodiq Kolawole Lawal; Carmen Olivia Rennie; Onyemaechi Okpara Azu
Journal:  Pharmacol Res Perspect       Date:  2021-05

10.  In vivo effect of statins on the expression of the HIV co-receptors CCR5 and CXCR4.

Authors:  Edwin A Higuita; Fabián A Jaimes; Maria T Rugeles; Carlos J Montoya
Journal:  AIDS Res Ther       Date:  2013-05-01       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.